Oncology News | pharmaphorum

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

Keytruda could get patient-friendly 6 week dosing schedule i...

US-based Merck & Co is putting further pressure on its arch-rival Bristol-Myers Squibb with a potential new six-week dosing schedule for some European patients taking its Keytruda (pemb

News

Bayer files prostate cancer drug darolutamide in Japan

Bayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the pressure on rivals Johnson & Johnson and Pfizer/Astellas.

News

Doubts over BMS-Celgene merger after Starboard intervention

Doubts are mounting about whether Bristol-Myers Squibb’s $74 billion merger with Celgene will go ahead after another key investor came out against the deal.

News

Advisers urge FDA to delay decision on Karyopharm cancer dru...

Advisers to the US drugs regulator have said a decision on whether to approve Karyopharm’s multiple myeloma combination should be delayed until the results of a phase 3 trial, due late this

News

AZ/Merck & Co's Lynparza delays spread of pancreatic cancer

AstraZeneca and Merck & Co’s Lynparza could offer a new option for certain patients with pancreatic cancer after a trial showed it slowed progression of the disease.

News

Two new cancer Priority Reviews for Roche

Roche has announced that the FDA has granted Priority Review to two of its drugs – personalised lung cancer medicine entrectinib and lymphoma treatment polat

Keytruda could get patient-friendly 6 week dosing schedule i...

Bayer files prostate cancer drug darolutamide in Japan

Doubts over BMS-Celgene merger after Starboard intervention

Advisers urge FDA to delay decision on Karyopharm cancer dru...

AZ/Merck & Co's Lynparza delays spread of pancreatic cancer

Two new cancer Priority Reviews for Roche

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks